(Q52195493)

26 April 2018

title

Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride. (English)

1 reference

26 April 2018

author name string

Trimble KM

series ordinal

1

1 reference

26 April 2018

Bell R

series ordinal

2

1 reference

26 April 2018

King DJ

series ordinal

3

1 reference

26 April 2018

language of work or name

English

0 references

publication date

1 April 1997

1 reference

26 April 2018

Pharmacology, Biochemistry and Behavior

published in

1 reference

26 April 2018

volume

56

1 reference

26 April 2018

issue

4

1 reference

26 April 2018

page(s)

809-816

1 reference

26 April 2018

Stimulation of brain dopamine autoreceptors by remoxipride administration in reserpine-treated male rats.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Differential performance of acute and chronic schizophrenics in a latent inhibition task.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride — an123I-IBZM single photon emission tomography (SPET) study

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Haloperidol enhancement of latent inhibition: Relation to therapeutic action?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Amphetamine-produced attenuation of latent inhibition is modulated by stimulus preexposure duration: implications for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Latent inhibition is unaffected by direct dopamine agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Long-term attentional deficit in nonhandled males: possible involvement of the dopaminergic system

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Biochemical pharmacology of the atypical neuroleptic remoxipride

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

A theory of attention: Variations in the associability of stimuli with reinforcement

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Comparison of the effects of haloperidol, remoxipride and raclopride on "pre"- and postsynaptic dopamine receptors in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Effects of the dopamine D2 selective receptor antagonist remoxipride on dopamine turnover in the rat brain after acute and repeated administration

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

MDL 73,147EF, a 5-HT3 antagonist, facilitates latent inhibition in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Concentrations of remoxipride and its phenolic metabolites in rat brain and plasma. Relationship to extrapyramidal side effects and atypical antipsychotic profile

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Is the sigma opiate receptor a proadifen-sensitive subform of cytochrome P-450?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

CNS dopamine autoreceptors: distribution, pharmacology, and function

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Neural substrates of latent inhibition: the switching model

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Facilitation of latent inhibition by haloperidol in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

The latent inhibition model of schizophrenic attention disorder and of antipsychotic drug action: comment on Dunn, Atwater and Kilts (Psychopharmacology, 1993, 112:315-323)

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

The effects of the new antipsychotic, sertindole, on latent inhibition in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

Disruption of latent inhibition by acute administration of low doses of amphetamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2896%2900483-2

7 January 2021

10.1016/S0091-3057(96)00483-2

Identifiers

DOI

1 reference

26 April 2018

PubMed ID

9130309

1 reference

26 April 2018